Songjiang Ma is President at GYRE THERAPEUTICS, INC. (GYRE). They have made 1 open-market trade across 1 company since 2024, most recently 2025-05-28.
CIK 0001985547
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| GYRE | 2,806,642 | $17.1M |
Shares reported on the most recent Form 4, priced at the 2025-05-29 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| GYRE | SELL · 10b5-1 | 2025-05-27 | 2025-05-29 | $10.23 | $26K | -7.2% | -24.2% | -16.4% |
| GYRE | SELL · 10b5-1 | 2025-05-22 | 2025-05-27 | $10.91 | $24K | -18.2% | -28.2% | -20.2% |
| GYRE | SELL · 10b5-1 | 2025-05-20 | 2025-05-22 | $11.04 | $44K | -7.3% | -16.1% | -16.5% |
| GYRE | SELL · 10b5-1 | 2025-05-16 | 2025-05-20 | $11.21 | $45K | -33.2% | -29.8% | -31.7% |
| GYRE | SELL · 10b5-1 | 2025-05-14 | 2025-05-16 | $10.69 | $22K | -14.3% | -27.3% | -25.5% |
| GYRE | SELL · 10b5-1 | 2025-05-12 | 2025-05-14 | $10.97 | $44K | -2.0% | -23.1% | -27.2% |
| GYRE | SELL · 10b5-1 | 2025-03-21 | 2025-03-25 | $10.00 | $2K | -25.8% | -2.1% | -16.6% |
| GYRE | SELL · 10b5-1 | 2025-03-19 | 2025-03-21 | $10.11 | $40K | -27.6% | -14.2% | -17.6% |
| GYRE | SELL · 10b5-1 | 2025-03-17 | 2025-03-19 | $11.89 | $27K | -24.7% | -18.0% | -21.1% |
| GYRE | SELL · 10b5-1 | 2025-03-13 | 2025-03-17 | $12.06 | $48K | -21.0% | -31.0% | -30.2% |
| GYRE | SELL · 10b5-1 | 2025-03-11 | 2025-03-13 | $11.57 | $46K | -20.4% | -35.2% | -29.2% |
| GYRE | SELL · 10b5-1 | 2025-03-07 | 2025-03-11 | $10.19 | $41K | -14.8% | -36.1% | -25.4% |
| GYRE | SELL · 10b5-1 | 2025-03-05 | 2025-03-07 | $10.89 | $44K | +1.7% | -24.6% | -21.2% |
| GYRE | SELL · 10b5-1 | 2025-03-03 | 2025-03-05 | $11.05 | $44K | +12.6% | -36.6% | -24.7% |
| GYRE | SELL · 10b5-1 | 2025-02-27 | 2025-03-03 | $11.37 | $45K | +8.0% | -36.0% | -30.6% |
| GYRE | SELL · 10b5-1 | 2025-02-25 | 2025-02-27 | $11.50 | $46K | +1.1% | -31.3% | -15.9% |
| GYRE | SELL · 10b5-1 | 2025-02-21 | 2025-02-25 | $11.30 | $45K | -11.2% | -21.8% | -12.4% |
| GYRE | SELL · 10b5-1 | 2025-02-19 | 2025-02-21 | $12.35 | $49K | -3.7% | -20.3% | -2.9% |
| GYRE | SELL · 10b5-1 | 2025-02-14 | 2025-02-19 | $12.22 | $49K | -6.3% | -20.4% | -6.6% |
| GYRE | SELL · 10b5-1 | 2025-02-12 | 2025-02-14 | $11.59 | $46K | -7.6% | +0.5% | -10.5% |
| GYRE | SELL · 10b5-1 | 2025-02-10 | 2025-02-12 | $11.72 | $45K | -2.4% | +3.3% | -1.9% |
| GYRE | SELL · 10b5-1 | 2025-02-06 | 2025-02-11 | $12.51 | $50K | -7.1% | +5.3% | -4.7% |
| GYRE | SELL · 10b5-1 | 2025-02-04 | 2025-02-06 | $12.01 | $48K | -3.2% | -17.6% | -29.4% |
| GYRE | SELL · 10b5-1 | 2025-01-31 | 2025-02-04 | $11.49 | $46K | -0.2% | -10.8% | -26.6% |
| GYRE | SELL · 10b5-1 | 2025-01-29 | 2025-01-31 | $11.40 | $46K | +1.5% | -0.2% | -18.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.